Page 12 - Risk Evaluation News Today

In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of careThe as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall responseLonger-term data from CARTITUDE-2 showed deep and durable respons...

PRINCETON, N.J.--(BUSINESS WIRE)--Dec 10, 2023--

Seven new agents have received FDA approval since October 2022.

"A significant wave [of JN.1] has started here and could be blunted with a high booster rate and mitigation measures."

(BPT) - When the COVID-19 pandemic hit in 2020, Ben, who had already been diagnosed with clinical depression in 2018, felt his depressive symptoms increase the more isolated he became.

Bristol Myers Squibbs Abecma® Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in Japan TOKYO,...

FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.

This marks the first oral monotherapy approved for the rare blood disorder.

(BPT) - When the COVID-19 pandemic hit in 2020, Ben, who had already been diagnosed with clinical depression in 2018, felt his depressive symptoms increase the more isolated he became.

(BPT) - When the COVID-19 pandemic hit in 2020, Ben, who had already been diagnosed with clinical depression in 2018, felt his depressive symptoms increase the more isolated he became.